Novel radiotracer rapidly detects gastrointestinal cancer biomarker, identifies patients for targeted therapy

(A) Patient 9 was woman with advanced gastric cancer whose CLDN18.2 expression level was 40%, 2+. Left pleural metastatic nodule (blue arrow) and thickened peritoneum (white arrow) did not show obvious uptake on 18F-FDG PET/CT, whereas 68Ga-NC-BCH PET/CT showed high uptake (SUVmax, 3.1 [red arrow] and 5.7 [green arrow]). (B) Patient 4 was man with colon cancer whose CLDN18.2 expression level was 40%, 3+. On 18F-FDG PET/CT, abdominal metastatic lymph node (white arrow) showed mild uptake, whereas same lymph nodes on 68Ga-NC-BCH PET/CT (blue arrow) showed high uptake (SUVmax, 1.4 Read More

Related posts:

  1. Novel CAR T therapy and shorter targeted therapy durations show promise for patients with leukemia
  2. Patients receiving exceptions to participate in targeted therapy trial have similar outcomes to eligible participants
  3. Researchers provide a review and update on therapy of gastrointestinal tract tumors
  4. High levels of novel biomarker GDF15 in steatotic liver patients linked to increased liver cancer risk
  5. Study finds no link between exposure to immunosuppressive therapy, cancer in IBD patients
  6. New therapy may rapidly reverse life-changing sepsis-induced brain injury, animal study suggests
  7. Acupuncture reduces hot flashes in breast cancer therapy patients, study finds
  8. New combination therapy shows promise for bladder cancer patients unresponsive to standard treatment

Leave a Reply

Your email address will not be published. Required fields are marked *